Next generation veterinary biologics
Kedi is pioneering new therapies for cats.
WHAT CATS FACE
Same diseases. Different care.
Veterinary medicine lags decades behind human medicine, and our own experience with this gap motivates us to close it.
We established a platform technology and built large datasets to develop monoclonal antibody and peptide therapies for cats.
Cancer
- IN CATS
- 1 in 5 cats are diagnosed with cancer; mostly lymphomas, oral carcinomas, mammary tumors or fibrosarcomas.
- CARE
- Treatment can involve surgery, radiation, or chemotherapy drugs borrowed from human medicine. Patient prognosis remains poor.
- KEDI-01 · KEDI-02
- We are developing two antibodies to drastically improve outcomes across the most prevalent types of feline cancer.
Allergy and itch
- IN CATS
- Cats suffer various allergic or atopic skin conditions, frequently with asthma, but these are poorly understood.
- CARE
- Antimicrobials and steroids are commonly used in feline dermatology. There are no approved biologic therapies in this area.
- KEDI-03
- We study feline dermatitis and advance a novel drug mechanism aiming to provide deep and durable relief to patients.
Obesity and diabetes
- IN CATS
- It is estimated that 30–60% of cats seen by vets are overweight or obese, which is associated with poor health outcomes.
- CARE
- Care rests on dietary changes and, once diabetes sets in, daily insulin injections or newer oral drugs. Behavioral adaptations are challenging.
- KEDI-04
- Inspired by GLP-1s, our feline multi-incretin aims to deliver a safe and convenient solution for weight management and diabetes.
Kidney diseases
- IN CATS
- Feline chronic kidney disease develops silently over years. It is poorly understood, yet is one of the leading causes of death.
- CARE
- Disease is managed rather than treated. Special diets and fluids can slow it, but a disease-modifying treatment approach is still lacking.
- KEDI-05
- Based on our own discoveries, we are developing an anti-fibrotic antibody with potential to become a breakthrough therapy.
Pain
- IN CATS
- Joint diseases (60–90% of older cats) and periodontal issues (>25% of cats) are common causes of pain, which cats hide very well.
- CARE
- NSAID (e.g. meloxicam) use is very common. Osteoarthritis-associated pain is the only indication with an approved feline monoclonal antibody.
- KEDI-06
- We built a research program with leading scientists to discover new possibilities for the management of pain with fewer side effects.
Proven drug formats, built natively for cats
Biologic therapies transformed human medicine and gave us a deeper understanding of immunology. Kedi aims to give veterinarians the same precision arsenal to care for our beloved companions.
OUR APPROACH
Monoclonal antibodies
Fc-fusion proteins
More soon…
Species-specific
We develop best-in-class monoclonal antibodies and peptides built on fully feline sequences.
AI-native
Our data and experimental infrastructure allow us to design and de-risk in tight, iterative loops.
Ethical
We discover and validate with high ethical standards, and without sacrificing animals.
We are inspired by mutualism. Kedi envisions and enables biologic R&D that is even more insightful, resource-efficient, and life-sustaining than it is today.


